Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 15/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148836 | 1.00 | TACR3 (0.46) | TACR3CYP2C9RIPK1SMYD3 | |
| SCHEMBL7951091 | 0.94 | TACR3 (0.42) | TACR3CYP2C9 | |
| SCHEMBL7946365 | 0.93 | TACR3 (0.45) | TACR3CYP2C9RIPK1SMYD3 | |
| SCHEMBL7948901 | 0.92 | CYP2C9 (0.50) | TACR3CYP2C9RIPK1 | |
| SCHEMBL7949103 | 0.91 | TACR3 (0.45) | TACR3CYP2C9RIPK1 | |
| SCHEMBL7954227 | 0.90 | PDE2A (0.42) | TACR3CYP2C9 | |
| SCHEMBL7954512 | 0.90 | TACR3 (0.39) | TACR3CYP2C9 | |
| SCHEMBL2149581 | 0.90 | TACR3 (0.43) | TACR3CYP2C9RIPK1SMYD3 | |
| SCHEMBL2169904 | 0.90 | TACR3 (0.48) | TACR3CYP2C9RIPK1 | |
| SCHEMBL16566393 | 0.89 | CYP2C9 (0.47) | TACR3CYP2C9SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371385-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | SOJOURNIX INC (US) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371385-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | HLA-DRB1, HLA-B, APBA1 | TACR3 3828/4885CYP2C9 1407/4885RIPK1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.